2025-12-17 - Analysis Report
Okay, here's a comprehensive analysis of Intuitive Surgical Inc. (ISRG) based on the data you provided, broken down into sections as requested:

**1) Return Rate Comparison with S&P 500 (VOO)**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **ISRG Cumulative Return:** 104.997%
*   **VOO Cumulative Return:** 99.807%
*   **Divergence Analysis:**
    *   **Divergence Range:** Max 98.9, Min -39.7
    *   **Current Divergence:** -2.6
    *   **Relative Divergence:** 26.8

**Analysis:** ISRG has outperformed the S&P 500 over the analyzed period, showing a higher cumulative return. The current divergence is -2.6%, meaning the stock is lagging very slightly behind. The relative divergence of 26.8 indicates that the current divergence is relatively low compared to its historical fluctuations.

*   **Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 68.0%  | 77.6% | 40.0%  | -0.1 | 43.6   |
| 2016-2018  | 64.0%  | 72.2% | 49.0%  | -0.0 | 57.2   |
| 2017-2019  | 54.0%  | 72.2% | 31.0%  | 0.2   | 70.6   |
| 2018-2020  | -6.0%  | 80.4% | -29.0% | 0.3   | 97.8   |
| 2019-2021  | 29.0%  | 80.4% | -18.0% | 0.6   | 128.8  |
| 2020-2022  | -23.0% | 80.4% | -22.0% | 1.2   | 95.1   |
| 2021-2023  | -17.0% | 77.5% | -18.0% | 1.7   | 120.9  |
| 2022-2024  | 36.0%  | 77.5% | 15.0%  | 1.7   | 187.1  |
| 2023-2025  | 67.0%  | 72.7% | 3.0%   | 0.8   | 198.8  |

*   **CAGR (Compound Annual Growth Rate):** Reflects the average annual growth rate over the period. It has been volatile, with significant growth in earlier periods (2015-2019) followed by periods of decline (2018-2023) and then a resurgence (2023-2025).
*   **MDD (Maximum Drawdown):** Indicates the largest peak-to-trough decline during the period. MDD has been consistently high, suggesting significant volatility.
*   **Alpha:** Measures the investment's performance relative to the market (S&P 500). Positive Alpha indicates outperformance, while negative Alpha indicates underperformance. Alpha has fluctuated, with some periods of strong outperformance (2015-2018) and others of underperformance (2018-2023).
*   **Beta:** Measures the investment's volatility relative to the market. A Beta of 1 indicates that the investment moves in line with the market. A Beta greater than 1 indicates higher volatility, and a Beta less than 1 indicates lower volatility. Beta has generally increased over time, suggesting that ISRG has become more volatile relative to the market.
*   **Cap(B) (Capitalization in Billions):** Shows the company's market capitalization at the end of each period. Market capitalization has generally increased over time, indicating growth in the company's overall value, but has also experienced fluctuations.
    

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 554.58
*   **Last-Market Details:** Price 554.58, Previous Close 559.52, Change -0.88
*   **5-day SMA:** 551.94
*   **20-day SMA:** 562.704
*   **60-day SMA:** 516.8068

**Analysis:**  The stock price is currently below its 20-day SMA, but above its 60-day SMA. The price decreased comparing to the previous day. The 5-day SMA is below the 20-day SMA, indicating a possible short-term downward trend.

**3) RSI, PPO, and Expected Return Analysis**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment Recommended)
*   **RSI:** 34.99 (Approaching Oversold)
*   **PPO:** -0.81 (Negative, indicating downward momentum)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent Divergence Change (20 days):** -4.3 (Indicates a short-term decline in relative performance)
*   **Expected Return (%):** 35.5% (Long-term forecast exceeding S&P 500)

**Analysis:** The MRI suggests a medium investment risk. The RSI is approaching oversold conditions (below 30), which could signal a potential buying opportunity. The negative PPO confirms the recent downward momentum. The recent divergence change supports this short-term bearish view. However, the high expected return suggests that analysts anticipate strong long-term growth for the stock.

**4) Recent News & Significant Events**

*   **Intuitive Surgical (ISRG) Stock News Today: What’s Driving Shares, Latest Analyst Forecasts, and Key Catalysts for 2026:** This suggests that market observers are closely monitoring the company's performance and future prospects.
*   **Is FDA Clearing da Vinci SP for General Surgery Altering The Investment Case For Intuitive Surgical (ISRG)?:** FDA clearance is a critical catalyst for Intuitive Surgical, expanding the use cases and market opportunities for the da Vinci system.
*   **Salem Investment Counselors Inc. Purchases 1,817 Shares of Intuitive Surgical, Inc.:** Institutional investors' activity indicates confidence in the stock's prospects.
*   **Intuitive Surgical Stock Hits Key Support - Buying Opportunity?:** Hitting a key support level might attract bargain hunters.
*   **ISRG vs. MDT: A High-Tech Robotics Faceoff in the Race for Leadership:** Competition between Intuitive Surgical and Medtronic is significant, and this comparison impacts investor sentiment.
*   **Intuitive Surgical Stock (ISRG) Opinions on 2025 Growth Guidance Update:** Growth guidance updates are essential for evaluating the company's future performance.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.06 (~Buy)
*   **Opinions:** 29
*   **Target Price:** 597.71 (avg) / 700.00 (high) / 378.00 (low)

**Analysis:** The analyst consensus is positive, with a buy rating and a significant number of opinions. The average target price suggests potential upside from the current price. However, the wide range between the high and low target prices indicates uncertainty among analysts.

**5) Recent Earnings Analysis**

*   **Earnings Table:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-22 | 1.98  | 2.51 B$    |
| 2025-07-23 | 1.84  | 2.44 B$    |
| 2025-04-23 | 1.95  | 2.25 B$    |
| 2024-10-18 | 1.59  | 2.04 B$    |
| 2025-10-22 | 1.59  | 2.04 B$    |

*   **Analysis:** Earnings per share (EPS) and revenue have generally increased over the past year. This indicates that the company is growing and becoming more profitable.

**6) Financial Information**

*   **Revenue and Profitability Table:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30 | $2.51B    | 66.36%        |
| 2025-06-30 | $2.44B    | 66.31%        |
| 2025-03-31 | $2.25B    | 64.69%        |
| 2024-12-31 | $2.41B    | 68.04%        |
| 2024-09-30 | $2.04B    | 67.41%        |

*   **Capital and Profitability Table:**

| Quarter      | Equity    | ROE     |
|--------------|------------|---------|
| 2025-09-30 | $16.93B  | 4.16%  |
| 2025-06-30 | $17.85B  | 3.69%  |
| 2025-03-31 | $17.11B  | 4.08%  |
| 2024-12-31 | $16.43B  | 4.17%  |
| 2024-09-30 | $15.58B  | 3.63%  |

*   **Analysis:** Revenue has consistently increased, indicating strong demand for Intuitive Surgical's products and services. The profit margin has remained relatively stable, suggesting efficient cost management. Equity has also increased over time, indicating a growing capital base. The Return on Equity (ROE) has fluctuated but remains at healthy level.

**7) Comprehensive Analysis**

*   **Summary:**

Intuitive Surgical (ISRG) is a strong company with a history of outperforming the S&P 500, as shown by cumulative return. Recent data indicates short-term downward momentum (price below 20-day SMA, negative PPO, negative divergence change). However, the RSI suggests the stock is approaching oversold conditions, which could present a buying opportunity.

*   **Strengths:**
    *   Strong historical performance compared to the market
    *   Positive analyst consensus with a "Buy" rating
    *   Increasing revenue and EPS, indicating growth and profitability
    *   High profit margins, suggesting efficient cost management
    *   Positive news regarding FDA clearance
*   **Weaknesses/Risks:**
    *   Recent downward price momentum
    *   Relatively high volatility (MDD)
    *   Competition with Medtronic
    *   Uncertainty among analysts, indicated by the wide range in target prices

*   **Overall:** Intuitive Surgical appears to be a fundamentally strong company with good long-term prospects. Despite some short-term headwinds and volatility, the positive analyst consensus, growth in revenue and earnings, and potential for expanding applications through FDA clearance make it an attractive investment for the long term.

**Disclaimer:** *This analysis is based solely on the data provided and should not be considered financial advice. Investors should conduct their own research before making investment decisions.*


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.